Trial Condition(s):

Atrial Fibrillation

Xarelto on prevention of stroke and noncentral nervous system systemic embolism in treatment-naïve Asian patients with non-valvular atrial fibrillation (XaMINA)

Bayer Identifier:

18981

ClinicalTrials.gov Identifier:

NCT03284762

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The purpose of the study is to collect additional information of Xarelto treatment in routine clinical practice. Patients affected by atrial fibrillation and who will get Xarelto as a prophylactic treatment against stroke and systemic embolism (Stroke Prevention in Atrial Fibrillation) will be observed.

Inclusion Criteria
- Female and male patients aged 19 years or older (Korea) and aged 20 years or older (Taiwan)
- Diagnosis of NVAF
- Patients for whom the decision to initiate treatment with rivaroxaban is made as per physician’s routine treatment practice
- Treatment naïve regarding stroke prevention for atrial fibrillation
- Signed informed consent
Exclusion Criteria
- Contraindications for rivaroxaban according to the local market authorization/summary of product characteristics (SmPC)
- Patients participating in an investigational program with interventions outside of routine clinical practice

Trial Summary

Enrollment Goal
1216
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Different facilities

Multiple Locations, Taiwan, China

Status
Completed
 
Locations

Different facilities

Multiple Locations, South Korea

Status
Completed
 

Trial Design